<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" version="2.0">

<channel>
	<title>BioHealth Investor</title>
	
	<link>http://www.biohealthinvestor.com</link>
	<description>Biotech and Medical Business Blog</description>
	<lastBuildDate>Fri, 06 Nov 2009 14:42:47 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.5</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" href="http://feeds.feedburner.com/BHI" type="application/rss+xml" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com" /><item>
		<title>ZIOPHARM Oncology (ZIOP) Presents R&amp;D, Shares React</title>
		<link>http://www.biohealthinvestor.com/2009/11/ziopharm-oncology-ziop-presents-rd-shares-react.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/ziopharm-oncology-ziop-presents-rd-shares-react.html#comments</comments>
		<pubDate>Fri, 06 Nov 2009 14:42:47 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[ZIOP]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2441</guid>
		
			<content:encoded><![CDATA[ZIOPHARM Oncology (NYSE:ZIOP) 
presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. As previously announced, having achieved the study-specified efficacy milestone following planned safety and efficacy review by the Data [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/ziopharm-oncology-ziop-presents-rd-shares-react.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA: Tumor Vaccines and Gene Therapy Products</title>
		<link>http://www.biohealthinvestor.com/2009/11/fda-tumor-vaccines-and-gene-therapy-products.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/fda-tumor-vaccines-and-gene-therapy-products.html#comments</comments>
		<pubDate>Fri, 06 Nov 2009 14:36:58 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[R&D]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2438</guid>
		
			<content:encoded><![CDATA[The FDA recently issued its latest &#8221;Development of Safe and Effective Tumor Vaccines and Gene Therapy Products&#8221; document.
Among the highlights:
*&#8221;Despite enormous efforts towards finding a cure and progress in some subsets, overall survival of cancer patients has not increased and new therapeutic approaches are warranted.&#8221;
*&#8221;Numerous investigational cancer gene therapies, tumor vaccines and immunotherapy products from industry, [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/fda-tumor-vaccines-and-gene-therapy-products.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Trap In Bioanalytical Systems (BASI)</title>
		<link>http://www.biohealthinvestor.com/2009/11/trap-in-bioanalytical-systems-basi.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/trap-in-bioanalytical-systems-basi.html#comments</comments>
		<pubDate>Thu, 05 Nov 2009 14:47:28 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[BASI]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2436</guid>
		
			<content:encoded><![CDATA[Bioanalytical Systems (NASDAQ:BASI) is up 63% on light volume and no news.
Watch for a sudden sell-off if profit takers look to make a killing
Douglas A. McIntyre<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/trap-in-bioanalytical-systems-basi.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Dip At Molecular Insight  (MIPI)</title>
		<link>http://www.biohealthinvestor.com/2009/11/a-dip-at-molecular-insight-mipi.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/a-dip-at-molecular-insight-mipi.html#comments</comments>
		<pubDate>Wed, 04 Nov 2009 14:52:23 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[General]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2429</guid>
		
			<content:encoded><![CDATA[Molecular Insight (NASDAQ:MIPI) is off about 10% today on no news.
The most recent announcement from the company was almost a week ago when it said it executed an exclusive 10-year agreement to supply the Onalta 90-Y edotreotide radiotherapeutic to BioMedica Life Sciences S.A., Athens, Greece.
In September, Molecular Insight entered into a Territory License Agreement with BioMedica [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/a-dip-at-molecular-insight-mipi.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novartis Expands China Vaccine Investments (NVS)</title>
		<link>http://www.biohealthinvestor.com/2009/11/novartis-expands-china-vaccine-investments-nvs.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/novartis-expands-china-vaccine-investments-nvs.html#comments</comments>
		<pubDate>Wed, 04 Nov 2009 14:52:19 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[flu]]></category>
		<category><![CDATA[vaccine]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2430</guid>
		
			<content:encoded><![CDATA[Novartis AG (NYSE: NVS) wants to get larger in teh realm of vaccines.  In China for that matter.  The Swiss drug giant has announced plans to buy an 85% majority stake in a privately held Chinese vaccine maker called Zhejiang Tianyuan.  The purchase price is roughly $125 million.
This is a tiny scratch on the surface [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/novartis-expands-china-vaccine-investments-nvs.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biogen Idec Invests In Alzheimer’s Disease (BIIB)</title>
		<link>http://www.biohealthinvestor.com/2009/11/biogen-idec-invests-in-alzheimers-disease-biib.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/biogen-idec-invests-in-alzheimers-disease-biib.html#comments</comments>
		<pubDate>Tue, 03 Nov 2009 22:14:25 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[alzheimer's]]></category>
		<category><![CDATA[BIIB]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2426</guid>
		
			<content:encoded><![CDATA[It seems that Biogen Idec Inc. (NASDAQ: BIIB) is investing further into Alzheimer&#8217;s Disease.  A company called Probiodrug AG, a biotech with a particular focus on Alzheimer&#8217;s disease, announced on Monday that it had successfully closed a Series B financing round. The total round came to above 36 million Euros or more than $52 million [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/biogen-idec-invests-in-alzheimers-disease-biib.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Do Flu Vaccines Need to Worry About Pain Killers? (GSK, AZN, SNE, NVS)</title>
		<link>http://www.biohealthinvestor.com/2009/11/do-flu-vaccine-need-to-worry-about-pain-killers-gsk-azn-sne-nvs.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/do-flu-vaccine-need-to-worry-about-pain-killers-gsk-azn-sne-nvs.html#comments</comments>
		<pubDate>Tue, 03 Nov 2009 16:43:31 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[flu]]></category>
		<category><![CDATA[vaccine]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[SNE]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2422</guid>
		
			<content:encoded><![CDATA[There is an interesting release out today showing that research from the University of Rochester Medical Center shows an inverse relationship between some of the more common pain killers or relievers and the effectiveness of flu shots.  While this does not impact the need for flu vaccines and while this probably won&#8217;t impact the sale [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/do-flu-vaccine-need-to-worry-about-pain-killers-gsk-azn-sne-nvs.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Questcor Pharmaceuticals (QCOR) Hit On Earnings</title>
		<link>http://www.biohealthinvestor.com/2009/11/questcor-pharmaceuticals-qcor-hit-on-earnings.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/questcor-pharmaceuticals-qcor-hit-on-earnings.html#comments</comments>
		<pubDate>Tue, 03 Nov 2009 14:41:00 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[QCOR]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2420</guid>
		
			<content:encoded><![CDATA[Questor (NASDAQ:QCOR) announced very disappointing earnings for the last quarter ending September 30.
Net sales totaled $13.9 million for the three months ended September 30, 2009 compared to $24.2 million in the year earlier period. Net income for the third quarter of 2009 was $1.2 million, or $0.02 per diluted common share compared to $9.0 million, [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/questcor-pharmaceuticals-qcor-hit-on-earnings.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Lupus Buster Unleashed! (HGSI, GSK)</title>
		<link>http://www.biohealthinvestor.com/2009/11/lupus-buster-unleashed-hgsi-gsk.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/lupus-buster-unleashed-hgsi-gsk.html#comments</comments>
		<pubDate>Mon, 02 Nov 2009 14:48:50 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[Lupus]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[genomics]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2416</guid>
		
			<content:encoded><![CDATA[Human Genome Sciences, Inc. (NASDAQ: HGSI) has spent 2009 as its year where the company acted as the rising Phoenix from the ashes.  Things had reached bad enough levels that the stock traded under the $1.00 mark.  But a surprising twist in its experimental lupus drug called Benlysta has created a major change of fate [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/lupus-buster-unleashed-hgsi-gsk.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vertex (VRTX) Powers Up On Hep C Results</title>
		<link>http://www.biohealthinvestor.com/2009/11/vertex-vrtx-powers-up-on-hep-c-results.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/vertex-vrtx-powers-up-on-hep-c-results.html#comments</comments>
		<pubDate>Mon, 02 Nov 2009 14:43:42 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[R&D]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2414</guid>
		
			<content:encoded><![CDATA[More than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response (SVR) with a telaprevir-based regimen according to results of an intent-to-treat (ITT) analysis announced today by Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ). The data from Study C208 will be presented in an oral [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/vertex-vrtx-powers-up-on-hep-c-results.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss><!-- Dynamic page generated in 0.293 seconds. --><!-- Cached page generated by WP-Super-Cache on 2009-11-06 09:42:50 -->
